John B Fiveash
Overview
Explore the profile of John B Fiveash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
3514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siwakoti K, Dalton A, Maas J, McDonald A, Marcrom S, Cardan R, et al.
Int J Part Ther
. 2025 Mar;
15:100740.
PMID: 40061450
Purpose: Robustness evaluation is critical for proton beam therapy (PBT) planning, but ideal robustness criteria are not clearly defined. Here, we compared robustness of PBT plans to published intensity-modulated radiation...
2.
Holdhoff M, Ye X, Strowd R, Nabors B, Walbert T, Lieberman F, et al.
Neurooncol Adv
. 2024 Oct;
6(1):vdae150.
PMID: 39371261
Background: Lisavanbulin (BAL101553) is a small, lipophilic, oral microtubule destabilizer with promising antitumoral activity observed in preclinical glioblastoma (GBM) models. Methods: This multicenter phase 1 study sought to determine the...
3.
Covington E, Stanley D, Sullivan R, Riley K, Fiveash J, Popple R
J Appl Clin Med Phys
. 2024 Aug;
25(8):e14444.
PMID: 39106407
No abstract available.
4.
McDonald A, Murdaugh D, Heinzman K, Cardan R, Jacob J, Fiveash J, et al.
J Neurosurg
. 2024 Apr;
141(3):634-641.
PMID: 38669700
Objective: Radiation therapy (RT) is used selectively for patients with low-grade glioma (LGG) given the concerns for potential cognitive effects in survivors, but prior cognitive outcome studies among LGG survivors...
5.
Fiveash J, Ye X, Peerboom D, Mikkelsen T, Chowdhary S, Rosenfeld M, et al.
PLoS One
. 2024 Jan;
19(1):e0291128.
PMID: 38285688
Purpose: AT-101 is an oral bcl-2 family protein inhibitor (Bcl-2, Bcl-XL, Mcl-1, Bcl-W) and potent inducer of proapoptotic proteins. A prior study of the parent compound, racemic gossypol, demonstrated objective...
6.
Batchelor T, Won M, Chakravarti A, Hadjipanayis C, Shi W, Ashby L, et al.
Neurooncol Adv
. 2023 Nov;
5(1):vdad116.
PMID: 38024244
Background: A randomized, phase II, placebo-controlled, and blinded clinical trial (NCT01062425) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, versus...
7.
Maas J, McDonald A, Cardan R, Snider J, Fiveash J, Kole A
Pract Radiat Oncol
. 2023 Sep;
14(1):e68-e74.
PMID: 37748679
Purpose: Robustness evaluation is increasingly used in particle therapy planning to assess clinical target volume (CTV) coverage in the setting of setup and range uncertainty. However, no clear standard exists...
8.
Brown M, Marcrom S, Patel M, Popple R, Travis R, McDonald A, et al.
Neurosurgery
. 2023 Jul;
93(6):1313-1318.
PMID: 37449861
Background And Objectives: There is wide variation in treatment planning strategy for central nervous system (CNS) stereotactic radiosurgery. We sought to understand what relationships exist between intratumor maximum dose and...
9.
Covington E, Stanley D, Sullivan R, Riley K, Fiveash J, Popple R
J Appl Clin Med Phys
. 2023 Jun;
24(10):e14058.
PMID: 37289550
Purpose: To commission and assess the clinical performance of a new commercial surface imaging (SI) system by analyzing intra-fraction motion from the initial cohort of patients treated with frameless stereotactic...
10.
Maas J, Dobelbower M, Yang E, Clark G, Jacob R, Kim R, et al.
Pract Radiat Oncol
. 2023 Jun;
13(5):466-474.
PMID: 37268193
Purpose: Stereotactic body radiation therapy (SBRT) is increasingly used as a definitive treatment option for patients with prostate adenocarcinoma. The aim of this study was to assess the late toxicity,...